



CLAIMS

1. A compound of formula I



wherein

R_a is H; C_{1-4} alkyl; or C_{1-4} alkyl substituted by OH, NH_2 , NHC_{1-4} alkyl or $N(di-C_{1-4}alkyl)_2$; one of R_b , R_c , R_d and R_e is halogen; C_{1-4} alkoxy; or C_{1-4} alkyl; and the other three substituents are H; or R_b , R_d and R_e are all H; and R is a radical of formula (a)



(a)

wherein

R_1 is $-(CH_2)_n-NR_3R_4$, wherein

each of R_3 and R_4 , independently, is H or C_{1-4} alkyl; or R_3 and R_4 form together with the nitrogen atom to which they are bound a heterocyclic residue;

n is 0, 1 or 2; and

R_2 is H; halogen; C_{1-4} alkyl; CF_3 ; OH; SH; NH_2 ; NO_2 ; C_{1-4} alkoxy; C_{1-4} alkylthio; NHC_{1-4} alkyl; $N(di-C_{1-4}alkyl)_2$ or CN;


or a salt thereof.

2. A compound according to claim 1 wherein R_a is H or methyl; one of R_b , R_c , R_d and R_e is methyl or ethyl and the other three substituents are H; or R_b , R_c , R_d and R_e are all H; R_2 is H; Cl, methyl or NO_2 ; n is 1; and each of R_3 and R_4 , independently, is H, methyl, ethyl or *i*-propyl; or R_3 and R_4 form together with the nitrogen atom to which they are bound a heterocyclic residue, or a salt thereof.


3. A compound according to claim 1 or 2 which is selected from
3-(2-Chloro-6-dimethylaminomethyl-naphthalen-1-yl)-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;
3-(2-Chloro 6-methylaminomethyl-naphthalen-1-yl)-4-(1H-indol-3-yl)-pyrrole-2,5-dione;
3-(6-Aminomethyl-naphthalen-1-yl)-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;
3-(2-Chloro-6-dimethylaminomethyl-naphthalen-1-yl)-4-(1H-indol-3-yl)-pyrrole-2,5-dione;
3-(2-Chloro-6-dimethylaminomethyl-naphthalen-1-yl)-4-(7-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;
3-(2-Chloro-6-methylaminomethyl -naphthalen-1-yl)-4-(7-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;
3-(6-Aminomethyl-naphthalen-1-yl)-4-(1H-indol-3-yl)-pyrrole-2,5-dione;
3-(6-Aminomethyl-naphthalen-1-yl)-4-(7-methyl-1H-indol-3-yl)-pyrrole-2,5-dione; or a salt thereof.
4. A compound according to any one of claim 1 to 3, in free form or in a pharmaceutically acceptable salt form, for use as a pharmaceutical.
5. A pharmaceutical composition comprising a compound according to any one of claim 1 to 3, in free form or in pharmaceutically acceptable salt form, in association with a pharmaceutically acceptable diluent or carrier therefor.
6. Use of a compound according to any one of claim 1 to 3, in free form or in a pharmaceutically acceptable salt form, or a pharmaceutical composition according to claim 5 in the manufacture of a medicament for treating or preventing diseases or disorders mediated by T lymphocytes and/or PKC.
7. Use of a compound according to any one of claim 1 to 3, in free form or in a pharmaceutically acceptable salt form, or a pharmaceutical composition according to claim 5 in the manufacture of a medicament for treatment and/or prevention of T-cell mediated acute or chronic inflammatory diseases or disorders, autoimmune diseases, graft rejection, cancer or infectious diseases.
8. A pharmaceutical combination comprising a compound according to any one of claim 1 to 3, in free form or in a pharmaceutically acceptable salt form, and a further agent selected

from immunosuppressant, immunomodulatory, anti-inflammatory, chemotherapeutic, antiproliferative and anti-diabetic agents.

9. A process for the production of the compound of formula I according to claim 1 or claim 2, which process comprises reacting a compound of formula II



wherein R_a ; R_b ; R_c , R_d and R_e are as defined in claim 1 and claim 2,
with a compound of formula III



wherein R is as defined in claim 1 and claim 2,
and, where required, converting the resulting compound of formula I obtained in free form to a salt form or vice versa, as appropriate.

10. A method for treating or preventing disorders or diseases mediated by T lymphocytes and/or PKC, in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound according to any one of claim 1 to 3, or a pharmaceutically acceptable salt thereof.